Get started
Author

Esther González-García

Observed names: Esther Gonzalez-Garcia, Esther Gonzalez-García, Esther González Garcia, Esther González García, Esther González‐García, González García, E, M. E. González, Maria Esther González, Maria-Esther Gonzalez, María-Esther Gonzalez
ORCID: 0000-0002-4238-0377
Observed ORCID: 0000-0002-4238-0377
OpenAlex ID: A5078500466
LAG-3 Blockade with Relatlimab (BMS-986016) Restores Anti-Leukemic Responses in Chronic Lymphocytic Leukemia
2021 · Christian Sordo-Bahamonde, Seila Lorenzo-Herrero, et al. · Cancers · 104
PDF
Expansion of NK Cells and Reduction of NKG2D Expression in Chronic Lymphocytic Leukemia. Correlation with Progressive Disease
2014 · Leticia Huergo-Zapico, Andrea Acebes-Huerta, et al. · PLoS ONE · 88
PDF
Lenalidomide and dexamethasone maintenance with or without ixazomib, tailored by residual disease status in myeloma
2023 · Laura Rosiñol, Albert Oriol, et al. · Blood · 69
PDF
BTLA/HVEM Axis Induces NK Cell Immunosuppression and Poor Outcome in Chronic Lymphocytic Leukemia
2021 · Christian Sordo-Bahamonde, Seila Lorenzo-Herrero, et al. · Cancers · 51
PDF
Ig-Like Transcript 2 (ILT2) Blockade and Lenalidomide Restore NK Cell Function in Chronic Lymphocytic Leukemia
2018 · Mónica Villa-Álvarez, Christian Sordo-Bahamonde, et al. · Frontiers in Immunology · 50
PDF
Definition and Clinical Significance of the Monoclonal Gammopathy of Undetermined Significance–Like Phenotype in Patients With Monoclonal Gammopathies
2023 · Leire Burgos, Luis-Esteban Tamariz-Amador, et al. · Journal of Clinical Oncology · 34
R‐COMP versus R‐CHOP as first‐line therapy for diffuse large B‐cell lymphoma in patients ≥60 years: Results of a randomized phase 2 study from the Spanish GELTAMO group
2021 · Juan‐Manuel Sancho, Rubén Fernández‐Alvarez, et al. · Cancer Medicine · 30
PDF
Lenalidomide and Chronic Lymphocytic Leukemia
2013 · Ana Pilar González-Rodríguez, Angel R. Payer, et al. · BioMed Research International · 26
PDF
Flow cytometry for fast screening and automated risk assessment in systemic light-chain amyloidosis
2018 · Noemi Puig, Bruno Paiva, et al. · Leukemia · 23
Refractoriness to immunochemotherapy in follicular lymphoma: Predictive factors and outcome
2017 · Marc Sorigue, Santiago Mercadal, et al. · Hematological Oncology · 22
Ig-like transcript 2 (ILT2) suppresses T cell function in chronic lymphocytic leukemia
2017 · Mónica Villa-Álvarez, Seila Lorenzo-Herrero, et al. · OncoImmunology · 19
PDF
The long term follow-up of early stage follicular lymphoma treated with radiotherapy, chemotherapy or combined modality treatment
2015 · Juan-Manuel Sancho, Olga García, et al. · Leukemia Research · 19
BTLA dysregulation correlates with poor outcome and diminished T cell-mediated antitumor responses in chronic lymphocytic leukemia
2023 · Christian Sordo-Bahamonde, Seila Lorenzo-Herrero, et al. · Cancer Immunology Immunotherapy · 15
PDF
The immune checkpoint LILRB4 promotes immune evasion and is correlated with disease progression and secondary malignancies in chronic lymphocytic leukemia
2025 · Christian Sordo-Bahamonde, Alejandra Martínez-Pérez, et al. · Biomedicine & Pharmacotherapy · 8
Immune biomarkers of increased infection risk in multiple myeloma
2026 · Aintzane Zabaleta, Luis-Esteban Tamariz-Amador, et al. · Blood · 5
The Mithralog EC-7072 Induces Chronic Lymphocytic Leukemia Cell Death by Targeting Tonic B-Cell Receptor Signaling
2019 · Seila Lorenzo-Herrero, Christian Sordo-Bahamonde, et al. · Frontiers in Immunology · 5
PDF
Cystatin C-Based Equations Detect Hidden Kidney Disease and Poor Prognosis in Newly Diagnosed Patients with Multiple Myeloma
2022 · Francisco-Javier Cepeda-Piorno, Esther González-García, et al. · Advances in Hematology · 3
PDF
Encefalopatía hiperamonémica como forma de presentación de un mieloma múltiple
2016 · Rubén Fernández-Álvarez, Esther González-García, et al. · Medicina Clínica · 2
Prevalence, Predictive Factors Therapy and Outcome of Patients with Follicular Lymphoma Refractory to First Line Immunochemotherapy
2015 · Marc Sorigue, Juan-Manuel Sancho, et al. · Blood · 2
Pb2182 Outcome of First‐line Therapy for Patients With Systemic Light‐chain Amyloidosis: Monocentric Analysis
2019 · R. Fernández, A. Silva Soto, et al. · HemaSphere · 1
R-COMP Vs. R-CHOP As First-Line Treatment for De Novo Diffuse Large B-Cell Lymphoma in Patients Older Than 60 Years: Preliminary Results from a Prospective Randomized Phase 2 Study from the Spanish Group Geltamo
2016 · Juan-Manuel Sancho, Francisco Gual, et al. · Blood · 1
PFS2 outcomes by prior therapy from DREAMM-8: A phase 3 study assessing belantamab mafodotin (belamaf), pomalidomide, and dexamethasone (BPd) vs pomalidomide, bortezomib, and dexamethasone (PVd) in patients (pts) with relapsed/refractory multiple myeloma (RRMM).
2026 · Güldane Cengiz Seval, Sosana Delimpasi, et al. · Journal of Clinical Oncology
Long-term outcomes with sustained minimal residual disease (MRD) negativity in belantamab mafodotin–treated patients (pts) with relapsed/refractory multiple myeloma (RRMM): An update from DREAMM-8.
2026 · Suzanne Trudel, Güldane Cengiz Seval, et al. · Journal of Clinical Oncology
Déficit adquirido del factor V, a propósito de un caso
2026 · Unibaso Iturregui, L, Cecchini Caballero, O, et al. · Zenodo (CERN European Organization for Nuclear Research)
The hematologist´s perspective. What to offer from the nutrition units
2024 · Esther González García, José Manuel Sánchez-Migallón Montul · Nutrición Hospitalaria
PDF
Works count: 27
Citation count: 577
H-index: 13
I10-index: 13
Year
Topic
Type